STAAR Surgical Company reported net sales of $76.0 million for the third quarter of 2022, a 30% increase compared to the prior year quarter. ICL sales increased by 33% and ICL unit growth was 40%. Net income was $10.3 million, or $0.21 per diluted share, compared to $6.0 million, or $0.12 per diluted share, for the prior year quarter.
Net sales increased by 30% to $76.0 million, with constant currency net sales up 37% from the prior year quarter.
ICL sales grew by 33% to $72.0 million, with constant currency ICL sales up 39% from the prior year quarter.
ICL unit growth was up 40% from the prior year quarter.
Net income was $0.21 per share, compared to $0.12 per share in the prior year quarter.
STAAR Surgical anticipates total net sales of approximately $285 million for fiscal 2022, which represents $300 million adjusted for constant currency. The fiscal 2022 outlook includes ICL sales of approximately $272 million, representing approximately 28% year over year growth, and Other Products sales of approximately $13 million. For fiscal 2023, the company expects to achieve approximately 30% ICL sales growth, year over year, to approximately $355 million in total company net sales which contemplates limited sales from Other Products.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance